Picture Source: Pictures of Getty
Creo Medical (Lese: Cree) has been a major disappointment in my cell and shared the EA. As I started investing at the beginning of 2023 (then last year, at a higher price), Penny stock was about 50%. Now is only 16p.
On 17 February, shareholders receive trading update from £ 65m medical Firm. Was there good? Let’s look at.
Mixed Update
AimSymbe chronic medical medical make up the attacker’s electrosurgical devices. The product of its SpeedBoaat can do many things – cut, and join, and Jova – one tool, eliminates the need for many tools.
The company has converted to the full-time sales section, and its devices are used at the growing number of hospitals. In the full-year update, however, we saw mixed results.
The 2024 income is expected to be approximately £ 30.4m, slowly down from 2023’s £ 30.8m. In addition, Creeo Core Technology technology increased by 74% to £ 4m, for a second half of the 50% sales growth. This includes sale from all basic products, including the recent Speedboat Ultraslim device. The administration said it was “New Customer Customer Customer at a time“.
Elsewhere, its new froase flex flexing device improves lung cancer guides. It is now working with Is the most accurate for surgery ‘System System in blocks of two UK hospocations. Many sites to keep in the near future, expecting this will be a revenue production after the first cases. Unfortunately, no money was found here.
In relation to 2025, the company said he did “True“Start Year, with trade in accordance with the expectations.
Best Ranking Position
Earlier this month, Croo has completed 51% of Creo Europe Coopeans Femal Micro technologyChinese company. Creeo Europe marks both of its food and third parties.
Following this, the party’s cash position was £ 31.2m. Means this is a strategic sale “It strengthens Cre Setwork Platform and enables CreE to continue supporting the development of the continuous technical strategies for its technical business“.
At that time, the company says it has reduced operating costs for £ 5m, with a complete benefit to identify this year. We will not know exactly how much the firm has been lost until the total receivables in April.
According to the Analysts in Edison, Cash-Flow Breakeven is now likely to be found in 2028 comparing 2025 before. Creeo, therefore, is expected to lose for a short time, obvious adds to the risk.
My thoughts
The correct agreement is still promising to me, with sites now make integrated lungs and processes included through the Robotic program and the CreBlate Flex Dex. This eventually may be a maximum stream of money.
The company also contains a dry powder of investing in its low-quality business, and I expect the important way to income from £ 4m. If that doesn’t happen, the stock may fall again.
I hope that he can recover, no matter, if I bear. Indeed, the seller’s seller repeatedly repeated its 70p target – more than 330% higher than the present levels (no guaranteed to end there, of course). Said now it is expecting Creeo to reach “Benefits Using Internal Internal Services“.
In 15p, the Creu may qualify to consider investors who endure risk. But I, I will keep the shares already holding, but I will never buy again.
Source link
